Boehringer and Lilly launch type 2 diabetes drug Jardiance in US with prescription
Jardiance, a once-daily, 10mg or 25mg tablet, was approved by the US Food and Drug Administration (FDA) on 1 August 2014 as an adjunct to diet and exercise
South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.